24127-59-1

Basic information

• Product Name: (4H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid Methyl ester
• Synonyms: (4H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid Methyl ester;(1H-1,2,4-Triazol-3-ylthio)acetic acid methyl ester;Methyl 2-((1H-1,2,4-triazol-5-yl)thio)acetate;methyl 2-((4H-1,2,4-triazol-3-yl)thio)acetate
• CAS NO: 24127-59-1
• Molecular Formula: C₅H₇N₃O₂S
• Molecular Weight: 173.19298
• EINECS: -0
• Mol File: 24127-59-1.mol

Chemical Properties

• Melting Point: 119-121 °C(Solv: hexane (110-54-3); benzene (71-43-2))
• Boiling Point: 344.3±44.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.62±0.20(Predicted)
• CAS DataBase Reference: (4H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid Methyl ester(24127-59-1)
• EPA Substance Registry System: (4H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid Methyl ester(24127-59-1)

Safety Data

• Hazardous Substances Data: 24127-59-1(Hazardous Substances Data)

Upstream product

• 96-32-2 bromoacetic acid methyl ester 
• 3179-31-5 1H-1,2,4-triazole-5-thiol 
• 3179-31-5 1H-[1,2,4]triazole-3-thiol 
• 39751-89-8 potassium 5-mercapto-1,3,4-triazole 
• 3179-31-5 3-mercapto-1,2,4-triazole 

Downstream Products

• 24127-58-0 (2H-[1,2,4]-triazol-3-ylsulfanyl)-acetic acid 
• 1241892-47-6 [1-(4-chlorophenylcarbamoyl)-1H-1,2,4-triazol-3-ylsulfanyl]acetic acid methyl ester 
• 898637-64-4 (1-phenylcarbamoyl-1H-1,2,4-triazol-3-ylsulfanyl)acetic acid methyl ester 
• 898637-62-2 [1-(4-chlorobenzenesulfonyl)-1H-1,2,4-triazol-3-ylsulfanyl]acetic acid methyl ester 
• 898637-61-1 (1-benzenesulfonyl-1H-1,2,4-triazol-3-ylsulfanyl)acetic acid methyl ester 
• 898637-60-0 [1-(toluene-4-sulfonyl)-1H-1,2,4-triazol-3-ylsulfanyl]acetic acid methyl ester 
• 1533519-85-5 2-((4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazole-3-yl)thio)acetic acid methyl ester 

Relevant articles and documents

Hydrophobicity and structure of 1,2,4-triazole derivatives bearing 1-carbamoyl and 3-sulfonyl groups

Various 3-sulfonyl-1,2,4-triazole-1-carboxamides (5a-h) were synthesized and their hydrophobicities were evaluated from their retention time in reversed-phase HPLC chromatography. Although the compounds have rather complex structures, a good linear relationship was observed between log k′ of these compounds derived from the retention time of HPLC and log PH for water-hexadecane partition coefficients of related alcohols. In regards with the rotation about the O2S-C(ester part) single bond, the preference for a gauche conformer relative to the anti form was revealed by both X-ray structural analysis of 5a and calculations at the AM1 level. In this conformation, substituents are arrayed to have the largest separation between the hydrophilic and hydrophobic parts. This can be rationalized as the primary reason for the good linearity.

URAT1 (uric acid transporter 1) inhibitors, and preparation method and application thereof

The invention provides carboxylic acid URAT1 inhibitors containing a naphthylmethyltriazole structure and represented by a general formula (I) which is described in the specification, a preparation method for the inhibitors, pharmaceutical compositions containing the inhibitors, and application of the inhibitors to preparation of drugs used for treating hyperuricemia and gout. The inhibitors as shown in the formula (I) have strong URAT1 inhibitory effect, normally have much stronger inhibitory effect compared with conventional URAT1 inhibitors with the structural characteristic that triazole and a naphthalene ring are directly linked by a covalent bond, and can be used as active ingredients for preparation of therapeutics used for treating gout and hyperuricemia. The inhibitors as shown inthe formula (I) are effective in wide dosage range; for example, the dosage of the inhibitors is about 1-1000 mg for each person each day.

Method for preparing Lesinurad intermediate

The invention belongs to the technical field of chemical synthesis, and particularly relates to a new method for preparing a lesinurad intermediate methyl 2-[[4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetate. The method comprises the following steps: (1) using 4-methyl-4H-3-thiol-1,2,4-triazole as the starting raw material to react with methyl bromoacetate or ethyl chloroacetate or phenyl bromoacetate under the action of the deacid reagent to generate methyl (4- methyl-4H-1,2,4-triazol-3-thio)acetate; subjecting the methyl (4- methyl-4H-1,2,4-triazol-3-thio)acetate to N-demethylase to generate methyl (4H-1,2,4-triazole-3-thio)acetate; (3) reacting the methyl (4H-1,2,4-triazole-3-thio)acetate with 1-bromo-4-cyclopropyl-naphthalene or 1-chloro-4-cyclopropyl-naphthalene to form the intermediate methyl 2-[[4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetate. The raw materials do not contain local toxic substances, and the production environment is relatively safe. The obtained product is high in yield and high in purity.

Synthesis of novel 1, 3-Substituted 1 H-[1, 2, 4]-Triazole-3-Thiol derivatives

By means of regioselective S-alkylation of 1 H-1, 2, 4-triazole-3-thiol (1), a series of S-substituted derivatives 2a-j were synthesized. In certain conditions, the reaction of 2 with arylsul-fochlorides, arylisocyanates, and quaternary ammonium salts of

Rationally designed 'dipeptoid' analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988

This paper outlines the synthesis of selected acid mimics of the non- peptide CCK-B selective antagonist CI-988, 1 CCK-B and CCK-A binding affinities of these analogues are described and their CCK-B affinity and selectivity rationalized by consideration o